by James Lyons-Weiler, PhD, Popular Rationalism, ©2026

(Feb. 3, 2026) — In the early 2010s, several European countries emerged as “pioneers” in offering gender-affirming medical interventions to minors experiencing gender dysphoria. These interventions included puberty blockers, cross-sex hormones, and in some cases, surgical procedures such as double mastectomies for adolescents. Clinics in the Netherlands, Sweden, and the United Kingdom became international reference points, and their protocols were emulated in other countries. Yet by the early 2020s, a sharp reevaluation was underway across Europe. Systematic reviews of the scientific literature, mounting evidence of regret and detransition, and concerns about the irreversible harms of early medicalization led public health authorities in multiple EU nations to revise or revoke earlier policies. The shift, grounded in evidence-based medicine rather than ideology, represents a profound transformation in pediatric care.
Sweden: A Cautionary Pivot
Sweden was among the first countries to restrict access to pediatric gender-affirming treatments after reviewing the available evidence. In 2021, the Swedish National Board of Health and Welfare (Socialstyrelsen) concluded that the scientific basis for puberty blockers and cross-sex hormones in adolescents was extremely weak. The Board declared that such interventions should only be offered in controlled research settings with full ethical oversight. The decision was reinforced by clinical observations at Karolinska University Hospital, which independently halted new puberty blocker prescriptions for minors. Swedish authorities cited specific risks, including impaired bone mineral density, uncertain effects on cognitive development, and irreversible changes in sexual function and fertility. A national reassessment of protocols emphasized that psychosocial support and psychotherapy should be the first-line responses to youth gender dysphoria.
Finland: Prioritizing Mental Health
Finland was the first country to explicitly repudiate the “affirmation-first” model in official guidance. The Council for Choices in Health Care (COHERE) issued updated recommendations in 2020 following an extensive evidence review. The Finnish guidance acknowledged that most adolescents with gender distress also have significant psychiatric comorbidities such as anxiety, depression, autism spectrum disorder, and trauma histories. Consequently, it advised that these conditions should be stabilized before any consideration of medical transition. COHERE found that evidence supporting hormonal and surgical interventions in youth was of low quality and insufficient to justify the risks. Hormones could be prescribed only under tightly controlled circumstances and typically not until adulthood. Psychological assessment and ongoing therapy were reaffirmed as central pillars of care.
United Kingdom: The Cass Review and the NHS Overhaul
In the United Kingdom, the National Health Service initiated a landmark independent review in 2020 under Dr. Hilary Cass to assess the safety and efficacy of gender services for children and adolescents. The Cass Review, released in interim form in 2022 and finalized in 2024, delivered a comprehensive critique of the previous clinical model. It found that the Gender Identity Development Service (GIDS) at the Tavistock Clinic operated with insufficient attention to underlying mental health conditions and lacked long-term outcome tracking. The review determined that the scientific evidence supporting puberty blockers and cross-sex hormones in youth was of very low certainty and did not justify routine use. Following the review, NHS England decommissioned the Tavistock Clinic and began restructuring services around regional centers with a holistic, mental-health-first approach. Puberty blockers are now considered investigational, and early social transition is discouraged without clear clinical benefit.
France, Norway, and Others: Echoes of Restraint
France’s National Academy of Medicine issued a public warning in 2022 urging caution in medical responses to childhood gender distress. It called for deeper psychological evaluation and warned that rising referrals of adolescent girls with no childhood history of gender dysphoria might reflect social contagion or unresolved psychological trauma. Similarly, Norway’s health authority released an expert review in 2023 labeling puberty blockers and cross-sex hormones for youth as experimental. These interventions were recommended only in clinical trial settings. Germany and the Netherlands, though historically more permissive, have begun updating protocols to increase emphasis on psychological evaluation and to introduce stricter eligibility criteria.
Harms Recognized and Detransition Acknowledged
Emerging data have shown that the risks associated with early medical transition are more serious and more common than initially believed. Adolescents placed on puberty blockers at Tanner Stage 2 and later advanced to cross-sex hormones face near-certain infertility and loss of sexual function if they never experience endogenous puberty. Known complications include impaired bone density, altered brain maturation, and chronic pelvic pain. Rates of regret and detransition, while previously reported as under 1%, have risen in recent observational data, particularly among young women who transitioned in adolescence. European authorities now acknowledge that some patients had transient gender distress driven by trauma, neurodevelopmental disorders, or internalized homophobia, which resolved over time.
Autistic youth have been found to be dramatically overrepresented in gender clinics. The Tavistock’s internal audit revealed autism spectrum characteristics in approximately one-third of referred patients, compared to 1–2% in the general population. This raises substantial concerns about diagnostic overshadowing, whereby gender dysphoria may be mistaken for identity confusion or rigidity commonly seen in neurodiverse individuals.
Reorienting Toward Evidence-Based, Ethical Care
Across Europe, the trajectory is clear: affirmation is no longer the default, and psychosocial evaluation is once again central to pediatric gender care. The concept of informed consent, particularly for irreversible interventions, is being reexamined in light of adolescents’ neurocognitive development. Countries such as Sweden and Finland now explicitly reject the notion that minors possess the maturity to consent to sterilization or surgical alteration of primary or secondary sex characteristics. European health agencies have begun to call for national registries, long-term follow-up studies, and outcome audits to understand the true efficacy and harms of these interventions.
Read the rest here.
